(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 January 2026 (02.01.2026)

WIPO | PCT

(10) International Publication Number
WO 2026/005855 A3

(51) International Patent Classification:
A61K 51/04 (2006.01) *A61P 35/00* (2006.01)
A61K 51/08 (2006.01) *C07K 7/50* (2006.01)

(21) International Application Number:
PCT/US2025/021145

(22) International Filing Date:
24 March 2025 (24.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/568,708 22 March 2024 (22.03.2024) US

(71) Applicant: **NUCLIDIUM AG** [CH/CH]; Im Erasmushaus, Baumleingasse 18, CH-4051 Basel (CH).

(72) Inventors: **JAAFAR-THIEL, Leila**; Im Erasmushaus, Baumleingasse 18, CH-4051 Basel (CH). **DE ROSE, Francesco**; Im Erasmushaus, Baumleingasse 18, CH-4051 Basel (CH). **SCHLESER, Sebastian Werner**; Im Erasmushaus, Baumleingasse 18, CH-4051 Basel (CH).

(74) Agent: **UITTO, Olivia** et al.; Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: INTEGRIN-TARGETING RADIOPHARMACEUTICALS AND USES THEREOF




FIG. 1

(57) Abstract: The present disclosure relates, in part, to radiopharmaceuticals that target integrin, such $\alpha_v\beta_6$, their pharmaceutical compositions, and their use in imaging, diagnosing, and treatment of conditions associated with overexpression of integrins as well as to methods of making these compositions, including high purity ^{61}Cu[Cu] radiopharmaceuticals that target integrins.

WO 2026/005855 A3

[Continued on next page]

(88) Date of publication of the international search report:
30 April 2026 (30.04.2026)

(15) Information about Correction:
see Notice of 12 March 2026 (12.03.2026)